L
Laura A. Demopoulos
Researcher at Merck & Co.
Publications - 38
Citations - 6381
Laura A. Demopoulos is an academic researcher from Merck & Co.. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 25, co-authored 38 publications receiving 6232 citations. Previous affiliations of Laura A. Demopoulos include United States Military Academy & Albert Einstein College of Medicine.
Papers
More filters
Journal ArticleDOI
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
Christopher P. Cannon,William S. Weintraub,Laura A. Demopoulos,Ralph Vicari,Martin J. Frey,Nasser Lakkis,Franz-Josef Neumann,Debbie H. Robertson,Paul DeLucca,Peter M. DiBattiste,C. Michael Gibson,Eugene Braunwald +11 more
TL;DR: In patients with unstable angina and myocardial infarction without ST-segment elevation who were treated with the glycoprotein IIb/IIIa inhibitor tirofiban, the use of an early invasive strategy significantly reduced the incidence of major cardiac events.
Journal ArticleDOI
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
Eric J. Topol,David J. Moliterno,Howard C. Herrmann,Eric R. Powers,Cindy L. Grines,David J. Cohen,Eric A. Cohen,Michel E. Bertrand,Franz-Josef Neumann,Gregg W. Stone,Peter M. DiBattiste,Laura A. Demopoulos,Target Investigators. Do Tirofiban,ReoPro Give Similar Efficacy Trial +13 more
TL;DR: The findings demonstrated that tirofiban offered less protection from major ischemic events than did abciximab, and the relative benefit of abcximab was consistent regardless of age, sex, the presence of diabetes, or the presence or absence of pretreatment with clopidogrel.
Journal ArticleDOI
Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial.
David A. Morrow,Christopher P. Cannon,Nader Rifai,Martin J. Frey,Ralph Vicari,Nasser Lakkis,Debbie H. Robertson,Darcy A. Hille,Paul DeLucca,Peter M. DiBattiste,Laura A. Demopoulos,William S. Weintraub,Eugene Braunwald +12 more
TL;DR: In patients with clinically documented acute coronary syndrome who are treated with glycoprotein IIb/IIIa inhibitors, even small elevations in cTnI and cTNT identify high-risk patients who derive a large clinical benefit from an early invasive strategy.
Journal ArticleDOI
Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18.
David A. Morrow,James A. de Lemos,Marc S. Sabatine,Sabina A. Murphy,Laura A. Demopoulos,Peter M. DiBattiste,Carolyn H. McCabe,C. Michael Gibson,Christopher P. Cannon,Eugene Braunwald +9 more
TL;DR: Elevated BNP at presentation identifies patients with non-ST-elevation ACS who are at higher risk of death and CHF and adds incremental information to cTnI and adds prognostic information to cardiac troponin I.
Journal ArticleDOI
The Effect of Routine, Early Invasive Management on Outcome for Elderly Patients with Non–ST-Segment Elevation Acute Coronary Syndromes
Richard G. Bach,Christopher P. Cannon,William S. Weintraub,Peter M. DiBattiste,Laura A. Demopoulos,H. Vernon Anderson,Paul DeLucca,Elizabeth M. Mahoney,Sabina A. Murphy,Eugene Braunwald +9 more
TL;DR: Clinical outcome by age in patients who were randomly assigned to an early invasive or conservative management strategy in the TACTICSTIMI 18 trial was analyzed to help resolve current uncertainties regarding appropriate management of elderly patients with nonST-segment elevation acute coronary syndromes.